The use of “low-quality data” is reasonable at the start of a crisis but FDA should consider raising the standard of evidence after multiple products come to market, according to the authors of the study.
The use of “low-quality data” is reasonable at the start of a crisis but FDA should consider raising the standard of evidence after multiple products come to market, according to the authors of the study.
Copyright © 2024 | WordPress Theme by MH Themes